Combined in-vivo and in-vitro capabilities for faster efficacy assessment
The two French contract research organizations (CROs), focusing on central nervous system pathologies, formed a strategic partnership to accelerate the efficacy assessment services that they provide to drug developers.
Neuron-Experts holds a portfolio of tests for the study of neuro-active compounds, based on primary neuronal cell cultures modeling neurodegenerative diseases and neuronal impairment-induced skin disorders.
Amylgen, on its side, provides in-vivo efficacy studies to its clients, with the potential to predict clinical trial results.
The joint offering that will be formed under the partnership, will provide an efficacy proof of concept to developers, allowing them to select the most effective compound among several leads.
Subsequently, the service provided will be able to further investigate the mechanism of action of the drug products and the ‘therapeutic strategy’ that should be followed, Amylgen stated.
Combination of in-vitro and in-vito testing has the potential to offer ‘great value’ in generating proof of concept during the evolution of the drug across the different development stages, commented Remy Steinschneider, CEO of Neuron-Experts.
Initially, the combined offering of the two companies will be focused on efficacy assessment of potential treatments for Alzheimer’s disease, with the service to be marketed by Amylgen.
According to Amylgen, the service will be ‘rapidly’ extended to other neurodegenerative diseases.
